A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Browse trials for

• Glaucoma 1,818
• Glaucoma, Open-Angle 929
• Ocular Hypertension 649
• Hypertension 6,689

Keywords

• open
• angle
• glaucoma
• ocular
• hypertension

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's enrollment of 87 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.

Lead sponsor

Alcon Research is the lead sponsor of 608 studies on the registry; 9 are open to participants now.

Of its 109 completed or terminated interventional studies of FDA-regulated products, 99 (91%) have results posted.

Study arms

• Experimental
  AL-37807 Suspension

  Drug: AL-37807 Ophthalmic Suspension, 1.0%

• Active comparator
  Xalatan

  Drug: Latanoprost, 0.005% (Xalatan)

• Placebo comparator
  AL-37807 Vehicle

  Other: AL-37807 Vehicle

• Experimental
  Timolol Maleate

  Drug: Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%

Interventions

• DrugAL-37807 Ophthalmic Suspension, 1.0%

  One drop in the study eye(s) once daily for 28 days

• DrugLatanoprost, 0.005% (Xalatan)

  One drop in the study eye(s) once daily for 28 days

  Also known as: XALATAN

• OtherAL-37807 Vehicle

  One drop in the study eye(s) once daily for 28 days

• DrugTimolol Maleate Ophthalmic Gel Forming Solution, 0.5%

  One drop in the study eye(s) once daily for 28 days

Primary outcomes

1. Mean intra-ocular pressure (IOP) change at Day 28 from baseline (Day 0)

   Time frame: Day 28